Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00717405
Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT00717366
- Locations
- 🇪🇸
Hospital Universitario La Paz: Nefrologia Pediatrica, Madrid, Spain
🇮🇹IRCCS G. Gaslini; U.O. Nefrologia, Dialisi e Trapianto, Genova, Liguria, Italy
🇪🇸Hospital Universitario la Fe; Servicio de Nefrologia Pediatrica, Valencia, Spain
A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.
Phase 4
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT00717314
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
Phase 1
Completed
- Conditions
- Pancreatic Neoplasm
- Interventions
- Biological: monoclonal antibodyDrug: chemotherapy
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT00711191
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
Not Applicable
Completed
- Conditions
- Human Papilloma Virus (HPV)
- Interventions
- Device: cobas® 4800 HPV Test
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47208
- Registration Number
- NCT00709891
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00701558
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT00700570
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 820
- Registration Number
- NCT00700102
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Carboplatin-based chemotherapy
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 303
- Registration Number
- NCT00700180
A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 351
- Registration Number
- NCT00699348
© Copyright 2025. All Rights Reserved by MedPath